Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology therapeutics,
merging the cytotoxic effect of conjugated payload with the high specific ability and …

PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor
activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in …

In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …

Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer
(NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for …

Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to
increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is …

Antibody-drug conjugates (ADCs) have become the cornerstone of effective therapeutics in
solid and hematological malignancies by harnessing potent cytotoxic payloads with targeted …

Advanced gastric adenocarcinoma is a common disease with a poor prognosis whose
treatment has for decades been based on cytotoxic chemotherapy, including platinum salts …

Human epidermal growth factor receptor 2 (HER2), coded by the proto-oncogene ERBB, is
known to be mutated or amplified in various malignant diseases, and many HER2-targeted …

Simple Summary Colorectal cancer (CRC) is the third most commonly diagnosed
malignancy and the second most common cause of cancer-related mortality worldwide …